Wrote this on June 17th:

After taking a 70% hit yesterday after the FDA asked for a recall of their homeopathic cold remedy Zicam, MTXX bounces as we predicted yesterday. The stock opened at $5.64 cents where we called it and then came just shy of seven bucks in trading today as panic subsided and shorts bought back to close their positions.

Matrixx Bounces As Predicted The Market Order

We’re glad to have gone along for the MTXX ride and were rewarded again today on news.

WASHINGTON, July 2 (Reuters) – Shares of Matrixx Initiatives (MTXX) soared as much as 30 percent on Thursday after the U.S. Food and Drug Administration released its official inspection report….The report noted that after the May 26-29 inspection, Matrixx’s vice president for research, development and product quality, told the inspector that the company had ‘nearly completed an extensive revision’ of its complaint procedures. Link to full text, FDA releases Zicam report, Matrixx stock rise - Forbes.com.

Do you own Matrixx stock (Nasdaq - MTXX)?

I work with a law firm investigating reports of possible securities law violations by Matrixx Initiatives, Inc., the maker of Zicam.

In a letter to Matrixx, the FDA concluded certain Zicam products may pose serious risks to consumers.

When the letter was released, Matrixx stock plummeted from approximately $19 per share to less than $7 per share. Since December 2007, insiders have sold more than $2.7 million worth of Matrixx shares.

Learn more: hbsslaw.com/matrixx

Hi all –

Thought you might be interested in this blog post by an attorney investigating Zicam maker Matrixx Initiatives (Nasdaq - MTXX).

As you may know, MTXX stock plummeted after an FDA letter to Matrixx about Zicam was released. Insiders got out by selling stock at the beginning, but where does that leave current shareholders?

Read the post here: http://tinyurl.com/njtpru

Do you own Matrixx stock (Nasdaq - MTXX)?

I work with a law firm investigating reports of possible securities law violations by Matrixx Initiatives, Inc., the maker of Zicam.

In a letter to Matrixx, the FDA concluded certain Zicam products may pose serious risks to consumers.

When the letter was released, Matrixx stock plummeted from approximately $19 per share to less than $7 per share. Since December 2007, insiders have sold more than $2.7 million worth of Matrixx shares.

Learn more: www.hbsslaw.com/matrixx